GangaGen Inc., a Palo Alto, Calif.-based developer of products to treat bacterial infections, has raised $5.4 million in Series E funding, according to a regulatory filing. Shareholders include ATEL Ventures, Otsuka Pharmaceutical Co. and ICF Ltd. www.gangagen.com